Formyl peptide receptors (FPRs) are expressed on a variety of leukocytes and play important roles in inflammation. Thus, FPR antagonists may represent novel therapeutics for modulating innate immunity and treating inflammatory diseases. Previously, 1H-pyrrol-2(5H)-ones were reported to be potent and competitive FPR1 antagonists. In the present studies, 42 additional 1H-pyrrol-2(5H)-one analogs were evaluated for FPR1 antagonist activity. We identified a number of novel competitive FPR1 antagonists that inhibited N-formylmethionyl-leucyl-phenylalanine (fMLF)-induced intracellular Ca 2+ mobilization in FPR1-transfected HL60 cells and effectively competed with WKYMVm-FITC for binding to FPR1 in FPR1-transfected RBL cells. The most active pyrroles inhibited human neutrophil Ca 2+ flux, chemotaxis, and adhesion to human epithelial cells, with the most potent being compounds 14 (4-benzoyl-1-hexy l-3-hydroxy-5-(4-hydroxy-3-methoxyphenyl)-2,5-dihydro-1H-pyrrol-2-one) and 17 (4-benzoyl-5-(2,5-dimethoxyphenyl)-3-hydroxy-1-(2-methoxyethyl)-2,5-dihydro-1H-pyrrol-2-one). In addition, these FPR1 antagonists inhibited fMLF-induced phosphorylation of extracellular signal-regulated kinases (ERK1/2) in FPR1-RBL cells, differentiated HL-60 cells, and human neutrophils. Most of the antagonists were specific for FPR1 and did not inhibit WKYMVM/WKYMVm-induced intracellular Ca 2+ mobilization in FPR2-HL60 cells, FPR3-HL60 cells, or interleukin 8-induced Ca 2+ flux in human neutrophils. Moreover, molecular modeling showed that the active pyrroles had a significantly higher degree of similarity with the FPR1 antagonist pharmacophore template as compared to inactive analogs. Thus, the 4-aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-one scaffold represents an important backbone for the development of novel FPR1 antagonists and could provide important clues for understanding the molecular structural requirements of FPR1 antagonists.
Introduction
Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCR) that play an important role in leukocyte activation and chemotaxis [1] . In humans, there are three FPR isoforms: FPR1, FPR2, and FPR3 [1] . FPR1 is expressed on a variety of cell types, including neutrophils, macrophages, natural killer (NK) cells, immature dendritic cells, astrocytes, microglial cells, hepatocytes, and bone marrow-derived mesenchymal stem cells [1] [2] [3] [4] [5] [6] . FPR1 was originally identified as a receptor for N-formyl peptides, which are produced by bacteria but can also be released from damaged mitochondria during tissue injury [2, 7, 8] . In phagocytes, FPR1 activation induces cell migration, the release of reactive oxygen http://dx.doi.org/10.1016/j.bcp.2017.07.004 0006-2952/Ó 2017 Elsevier Inc. All rights reserved. species (ROS), and phagocytosis [1, 4] . In addition to its role in phagocyte activation, FPR1 seems to have physiological roles in other cell types. For example, N-formylmethionyl-leucyl-phenylala nine (fMLF) induces osteoblast differentiation and upregulates expression of osteogenic markers [9] . Likewise, fMLF suppresses adipocyte differentiation in human mesenchymal stem cells [9] . Annexin A1 peptides can also activate FPR1 similar to N-formyl peptides and induce inflammatory responses [10] . Recently, it was found that FPR1 binds scolopendrasins, which are antimicrobial peptides from Scolopendra subspinipes mutilans [11, 12] . Cytokine-like proteins FAM19A4 (family with sequence similarity 19 member A4) and FAM3D (family with sequence similarity 3 member D) were also reported as a novel FPR1 ligands [13, 14] , and FAM19A4 was shown to stimulate chemotactic migration, phagocytosis, and release of ROS in macrophages via FPR1 [13] . FPR1 has been reported to contribute to the pathogenesis of several diseases. For example, FPR1 expression is associated with tumor progression and survival in gastric cancer [15] , and FPR1 mediates the tumorigenicity of human hepatocellular carcinoma cells [16] . High expression of FPR1 in neuroblastoma primary tumors corresponds with high-risk disease and poor patient survival [17] . Likewise, interaction of endogenous annexin A1 with FPR1 leads to transactivation of the epithelial growth factor receptor (EGFR), which promotes invasion and growth of glioma cells [18] . Gliadin, the immunogenic component within gluten and a trigger of celiac disease, induces neutrophil migration via engagement of FPR1 [19] . The efficacy of FPR1 blockade in hepatic ischemia-reperfusion injury was reported recently [20] . In addition, an aurantiamide analog HCH6-1 demonstrated protective effects on lipopolysaccharide-induced acute lung injury by blocking FPR1 in mice [21, 22] . Thus, bioactive ligands acting as FPR1 antagonists might serve as useful therapeutics in host defense in order to reduce detrimental effects associated with inflammation and cancer [23] .
Currently, the most potent FPR1-specific antagonists described are the fungal cyclic peptides, cyclosporine A and H [24] . However, in vivo studies of cyclosporines should be interpreted carefully, because their main therapeutic effects appear to involve signaling pathways unrelated to FPR1 [25] [26] [27] . However, growing evidence supporting the anti-inflammatory and tissue-protective effects of FPR1 antagonists led to the screening of natural products and commercial libraries for novel small-molecule FPR1 antagonists. As result of these screening efforts and/or structure-activity relationship (SAR)-directed design and synthesis, a number of synthetic non-peptide FPR1 antagonists with a wide range of chemical diversity have been identified (reviewed in [28, 29] ). In addition, a variety of natural molecules have been shown to be FPR1 antagonists [30] . Among the most potent and specific small-molecule FPR1 antagonists are compounds with a 4H-chromen-4-one scaffold [31] . Several FPR1 antagonists with a 4-aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-one scaffold were previously reported [32, 33] (Fig. 1 ), but their activities in primary cells, SAR analysis of related compounds, as well as molecular modeling have not been described. It should be noted that compounds having the same scaffold were also reported as small molecule blockers of the interaction between S100A10 and annexin A2 [34] . Because both annexin A2 and FPR1 are involved in pathogenesis of tumor growth and invasion of neuroblastoma, glioma, and hepatocellular carcinoma [35] [36] [37] , development of FPR1 antagonists based on the 4-aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-one scaffold could lead to promising dual functional agents for the treatment of these diseases.
In the present study, we evaluated forty-two 1H-pyrrol-2(5H)-ones for their ability to antagonize FPR-dependent signaling in neutrophils and FPR-transfected cells and identified novel and relatively potent FPR1 antagonists. Most of these antagonists were specific for FPR1 and did not inhibit FPR2-, FPR3-, or chemokine (C-X-C motif) receptor (CXCR) 1/2-dependent responses. SAR analysis of these compounds revealed the importance of a small hydrophobic group at position R 4 of the 4-aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-one scaffold. In addition, molecular modeling showed a high degree of similarity for low-energy conformations of these antagonists with the pharmacophore model of FPR1 antagonists.
Materials and methods

Materials
Dimethyl sulfoxide (DMSO), fMLF, 4-(2-hydroxyethyl)pipera zine-1-ethanesulfonic acid (HEPES), and Histopaque 1077 were from Sigma Chemical Co. (St. Louis, MO, USA). Dulbecco's Modified Eagle Medium (DMEM), Roswell Park Memorial Institute (RPMI) 1640 medium and penicillin-streptomycin solution were from Mediatech (Herdon, VA, USA). DMEM/F12 was from Lonza (Walkersville, MD, USA). Fetal bovine serum (FBS) was from Atlas Biolog- 
Cell culture
Human promyelocytic leukemia HL60 cells stably transfected with FPR1 (FPR1-HL60 cells) or FPR2 (FPR2-HL60 cells) were cultured in RPMI 1640 medium supplemented with 10% heatinactivated fetal calf serum, 10 mM HEPES, 100 lg/ml streptomycin, 100 U/ml penicillin, and G418 (1 mg/mL), as described previously [38] . Rat basophilic leukemia (RBL-2H3) cells transfected with human FPR1 (FPR1-RBL) were cultured in DMEM supplemented with 20% (v/v) FBS, 10 mM HEPES, 100 lg/ml streptomycin, 100 U/ml penicillin, and G418 (250 lg/ml), as described previously. Although stable cell lines are cultured under G418 selection pressure, G418 may affect some assays, so it was removed in the last round of culture before assays were performed. Wild-type HL60 and RBL-2H3 cells were cultured under the same conditions, but without G418. For differentiation of HL60 into neutrophil-like cells, DMSO was added to a final concentration of 1.2%, and the cells were cultured for 6 days. Differentiation was monitored by a gain of the responsiveness of cells to fMLF by measuring fMLF-induced superoxide generation (data not shown). Human T84 colonic adenocarcinoma cells were cultured in DMEM/F12 1:1 media supplemented with 10% (v/v) FBS, 15 mM HEPES, 100 lg/ml streptomycin, and 100 U/ml penicillin.
Isolation of human neutrophils
Blood was collected from healthy donors in accordance with a protocol approved by the Institutional Review Board at Montana State University. Neutrophils were purified from the blood using dextran sedimentation, followed by Histopaque 1077 gradient separation and hypotonic lysis of red blood cells, as previously described [39] . Isolated neutrophils were washed twice and resuspended in HBSS À . Neutrophil preparations were routinely >95% pure, as determined by light microscopy, and >98% viable, as determined by trypan blue exclusion.
Ca 2+ mobilization assay
Changes in intracellular Ca 2+ were measured with a FlexStation II scanning fluorometer (Molecular Devices, Sunnyvale, CA, USA), as described previously [38] . Antagonist activity and selectivity were evaluated after a 30 min pretreatment with test compounds at room temperature, followed by addition of peptide/chemokine agonist (5 nM fMLF, 5 nM WKYMVm, 10 nM WKYMVM, or 25 nM IL-8). In some experiments, a range of fMLF concentrations was used. Maximum change in fluorescence during the first 3 min, expressed in arbitrary units over baseline, was used to determine a response. Responses for FPR1 antagonists were normalized to the response induced by 5 nM fMLF for FPR1-HL60 cells and neutrophils, which were assigned a value of 100%. Curve fitting (5-6 points) and calculation of median effective inhibitory concentrations (IC 50 ) were performed by nonlinear regression analysis of the dose-response curves generated using Prism 7 (GraphPad Software, Inc., San Diego, CA, USA). Efficacy is expressed as % inhibition by an antagonist of the response induced by 5 nM fMLF at the maximal applied concentration of an antagonist ($50 mM). 50 ) were performed by nonlinear regression analysis of the dose-response curves generated using Prism software.
Chemotaxis assay
Competition binding assay
Dose-response assays were performed to measure test compound competition with the high-affinity fluorescent ligand WKYMVm-FITC for binding to human FPR1 in RBL transfected cells, as described previously [33] . Briefly, FPR1-RBL cells were preincubated with different concentrations of test compound for 30 min at 4°C, followed by addition of 0.5 nM WKYMVm-FITC. After incubation for an additional 30 min at 4°C, the samples were immediately analyzed using flow cytometry (LSRII, BD Biosciences, San Jose, CA, USA) without washing. The assay response range was defined by replicate control samples containing 1 mM of unlabeled fMLF (positive control) or buffer (negative control). In an individual dose-response experiment, each compound was tested in duplicate, resulting in 9 data points. The ligand competition curves were fitted by Prism software using nonlinear least-squares regression in a sigmoidal dose-response model to determine the concentration of added test com-pound that inhibited fluorescent ligand binding by 50% (i.e., IC 50 ). In equilibrium binding experiments with the labeled ligand, the K d values for FPR1 in RBL-FPR1 cells were found to be $0.5 and 0.4 nM, respectively. K i values were calculated from IC 50 , as reported previously [33] .
Neutrophil adhesion assay
Neutrophil adhesion to confluent T84 epithelial cells was evaluated as described previously [40] with modifications. Briefly, T84 epithelial monolayers were seeded at a density of 2 Â 10 5 T84
cells/well in 96-well plates and grown overnight. Human neutrophils were labeled for 30 min at 37°C with BCECF-AM (5 mM final concentration) and washed three times with HBSS À . The BCECF-labeled neutrophils were then added to the epithelial monolayers (10 5 cells/monolayer), followed by the addition of test compounds at the indicated concentrations or 1% DMSO (vehicle control). After a 10-min pre-incubation, 10 nM fMLF was added, the plates were centrifuged at 150g for 4 min to uniformly settle the neutrophils and synchronize the process, and adhesion was allowed for 10 min at 37°C. The monolayers were gently washed three times with HBSS À , and fluorescence intensity (excitation, 485 nm; emission, 530 nm) was measured on a Fluoroscan Ascent FL microplate reader. Adherent cell numbers were determined from standard curves generated by serial dilutions of known neutrophil numbers.
ERK phosphorylation assay
Phosphorylation of p44/42 mitogen-activated protein kinases (ERK1/2) was determined based on activation-associated phosphorylation. Both neutrophil-like HL60 cells and FPR1-transfected RBL cells were used. Cells cultured in six-well plates were serum starved for 4 h before stimulation. Samples were treated with the indicated concentrations of the compounds under investigation or 0.5% DMSO (vehicle) for 10 min and then stimulated with fMLF (20 nM) for 5 min. The reactions were terminated by adding 150 ll of ice-cold SDS-PAGE loading buffer.
Samples were analyzed by SDS-PAGE and Western blotting using rabbit anti-ERK1/2 (9102) and rabbit anti-ERK1/2 phosphorylated at Thr202 and Tyr204 (9101) (1:1000; Cell Signaling Technology, Inc., Danvers, MA, USA). Horseradish peroxidase-conjugated AffiniPure goat anti-rabbit IgG (1:3000; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) was used as secondary antibody. The immunoblots were visualized using a SuperSignal West Pico Chemiluminescence kit (ThermoFisher Scientific, Rockford, IL, USA) according to the manufacturer's instructions. The levels of phosphorylated ERK1/2 were determined by densitometry using NIH ImageJ software (NIH, Bethesda, MD) and normalized against total ERK1/2 on the same blot (n = 3). The results are expressed as relative phosphorylation of ERK1/2. For determination of ERK1/2 phosphorylation in human neutrophils, the cells were incubated for 10 min with the selected compounds or negative control (1% DMSO) at 37°C, followed by addition of 10 nM fMLF. The cells were lysed by adding lysis buffer (R&D Systems), and the levels of phosphorylated ERK1/2 were measured in the cell lysates using an ELISA kit for human phospho-ERK1 (Thr202/Tyr204)/ERK2 (Thr185/Tyr187) (R&D Systems). The concentrations of phospho-ERK1/2 in the cell lysates were determined using a SuperSignal West Pico Chemiluminescence kit.
Assessment of compound cytotoxicity
Cytotoxicity was analyzed with a CellTiter-Glo Luminescent Cell Viability Assay Kit (Promega, Madison, WI, USA), according to the manufacturer's protocol. Briefly, HL60 cells (wild-type) were cultured at a density of 1 Â 10 5 cells/well with different concentrations of compound under investigation for 18 h at 37°C and 5% CO2. Following treatment, the cells were allowed to equilibrate to room temperature for 30 min, substrate was added, and the samples were analyzed with a Fluoroscan Ascent FL microplate reader.
Molecular modeling
For pharmacophore modeling, we used a ligand-based approach for molecular modeling known as field point methodology, as described previously [31] . The structures of compounds were preoptimized by the semiempirical PM3 method using HyperChem 8.0 software and saved in Tripos MOL2 format. The structures were then imported into the FieldAlign program (FieldAlign Version 2.0.1; Cresset Biomolecular Discovery Ltd., Hertfordshire, UK). We used S-enantiomers of compounds for modeling, as preliminary studies demonstrated that FPR1 antagonists 1, 2, 15, and 17 in their S-configurations exhibited a noticeably higher degree of similarity to the pharmacophore template than the corresponding R-enantiomers. The conformation hunter algorithm incorporated in FieldAlign was used to generate representative sets of conformations corresponding to local minima of energy calculated within the extended electron distribution force field [41, 42] . Up to 200 conformations with specific field point patterns were obtained for each molecule. For the generation of field point patterns, probe atoms having positive, negative, and zero charge were placed in the vicinity of a given conformation, and the energy of their interaction with the molecular field was calculated using the extended electron distribution parameter set. Positions of energy extrema for positive probes give ''negative" field points, whereas energy extrema for negative and neutral probe atoms correspond to ''positive" and steric field points, respectively. Hydrophobic field points were also generated with neutral probes capable of penetrating into the molecular core and reaching extrema in the centers of hydrophobic regions (e.g., benzene rings). The size of a field point depends on magnitude of an extremum. The field points are colored according to the following convention: blue, electron-rich (negative field, i.e. obtained with a positive probe); red, electron-deficient (positive field, i.e. obtained with a negative probe); yellow, van der Waals attractive (steric); and orange, hydrophobic. A detailed description of the field point calculation procedure has been published elsewhere [43] .
A pharmacophore template based on known active FPR1 antagonists was also imported into the FieldAlign program. The template was created previously as a superimposition of the bioactive conformations of three potent FPR1 antagonists: 7-acetoxy-6-ethyl-2 -methyl-3-(1-methylbenzimidazol-2-yl)-4-oxo-chromene, (S)-N-( 1-(benzimidazol-2-yl)-3-(methylthio)propyl)-5-ethoxy-3-methyl benzofuran-2-carboxamide, and 6-benzyl-3-(2-chlorophenyl)-5-methyl-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7(1H)-one [31] . The molecules under investigation were then superimposed onto the template, taking into account mutual correspondence of field points. Superimpositions with the best similarity scores were collected. Statistical analysis of the similarity scores was performed with the use of ANOVA methodology as implemented in STATISTICA 8.0 software. The FPR1 homology model was created using the crystal structure of bovine rhodopsin, as reported previously [44] and imported into Molegro Virtual Docking (MVD) software (MVD 2010.4.2, MolegroApS) together with the structures of modeled compounds, and docking computations were performed using a spherical search space, as reported previously [45] .
Results
SAR analysis of pyrrole-based FPR1 antagonists
Based on structures of three published FPR1 antagonists 1-3 with a 4-benzoyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-one scaffold [32, 33] (Fig. 1) , 42 additional analogs were selected and evaluated for FPR1 antagonist activity in FPR1-HL60 cells by monitoring effects on fMLF-induced Ca 2+ mobilization. As result of this secondary screening, 18 novel FPR1 antagonists (45.2%) were identified, with the most potent compounds being 4 and 17 (Table 1) , supporting the significance of this scaffold for FPR1 antagonist activity. Analysis of derivatives with an unsubstituted R 1 showed that replacement of the terminal methyl group at R 4 with a methoxy group (compare 4 and 17) did not change FPR1 antagonist activity. However, more bulky substitution with morpholine (41) decreased activity, and subsequent replacement of the terminal methyl group with dimethylamino, dimethylaminomethyl, or diethylamino groups (compounds 29, 33, and 39, respectively) resulted in a complete loss of FPR1 antagonist activity. Similarly, in the series of derivatives with a methyl group at R 1 , compounds containing normal or branched alkyl groups (2 and 15) or a methoxy group (18) at R 4 were highly active FPR1 antagonists. Derivatives with nitrogencontaining R 4 groups, such as N-morpholino (42) or dimethylamino alkyl groups (30 and 34), were completely inactive. If the alkoxy chain at R 4 was elongated to three carbons, activity was increased 2-fold (compare 20 and 27). Although compound 41 containing a morpholine group at R 4 was active, additional introduction of a methyl group at position R 1 or methoxy group at R 2 was associated with complete loss of activity (compounds 42 and 43, respectively). All other compounds with 3-(N-morpholino)-1-propyl (40 and 44), 2-(dimethylamino)ethyl (28, 31, 32 ) and 3-(dimethylamino)-1-propyl (35 and 36) groups were also inactive. Thus, although a long aliphatic chain at R 4 (up to 6 carbon atoms; e.g. compare compounds 14 and 15) can be beneficial, nitrogencontaining substituents at this position are generally detrimental, perhaps, due to higher basicity of these groups.
No clear SAR emerged from modification of other positions of the molecules. However, moving the CH 3 group from R 2 to R 3 did not affect activity (compare 20 and 21). Introduction of a methoxy group led to complete loss of activity (compare 41 and 43). Note that all three reference compounds (1-3) that were previously discovered have methoxy groups at R 5 and R 7 , suggesting the importance of these groups for FPR1 antagonist activity. Although we did not extensively explore substitutions at these positions, elimination of one methoxy group at R 7 decreased activity 2-fold (compare 20 and 24). Similarly, elimination of the methoxy group at R 7 or moving this group to R 6 had a detrimental effect as well (compare compound pairs 18/19 and 16/17). However, elimination of the methoxy group at position R 6 did not affect activity (compare 22 and 26). Similarly, replacing the methyl group at R 6 with ethyl groups had no effect on FPR1 antagonist activity (compounds 23 and 25, respectively).
Competition binding of pyrrole-based FPR1 antagonists
All active compounds were analyzed for their ability to compete with WKYMVm-FITC for binding to FPR1, as described previously [31] , and values of the calculated binding constants (K i ) are presented in Table 1 . As an example, a representative dose-response curve of competitive inhibition of WKYMVm-FITC binding by compound 4 in FPR1-RBL cells is shown in Fig. 2. Compounds 4, 15 Table 2 ). The reason for the broad inhibitory activity of this compound is not clear; however, its lack of specificity indicates it would not be useful to target FPR1. Activation of neutrophils by fMLF induces various neutrophil function responses, including chemotaxis and adhesion [46] . Thus, to further investigate the effects of the FPR1 antagonists on these human neutrophil functions, we first evaluated the effects of these compounds on neutrophil chemotaxis. All compounds dosedependently inhibited fMLF-induced neutrophil migration, with IC 50 values of 2.2 to 36.3 mM ( Table 2) . As an example, representative dose-response curves for the inhibition of fMLF-induced neutrophil chemotaxis by compounds 14 and 17 are shown in Fig. 3B . We next evaluated the ability of selected FPR1 antagonists to inhibit neutrophil adhesion to epithelial cells. As with previous studies [47] , fMLF stimulated neutrophil adhesion in a concentrationdependent fashion with a EC 50 value of $7.5 nM. Consistent with the chemotaxis results, fMLF-induced neutrophil adhesion was significantly inhibited by most of the selected pyrrole-based FPR1 antagonists, with IC 50 values of 1.1-25.8 mM (Table 2) , and representative dose-response curves for the inhibition of fMLFinduced neutrophil adhesion by compounds 14 and 17 are shown in Fig. 4 . Note, however, that the compounds with the lowest binding activity (compounds 6 and 16) were inactive in this assay. Interestingly, compound 15 actually enhanced fMLF-induced neutrophil adhesion to epithelial cells. Likewise, this compound was the only pyrrole that inhibited Ca 2+ mobilization activated via FPR2 and CXCR1/2 ( antagonists was also in this range (r = 0.73, n = 13) [31] . The reason for the low correlation between these activities for the FPR1 antagonists is currently not understood. One likely contributor to lack of correlation between Ca 2+ flux and downstream function responses in studying receptor pharmacology is the times involved in these assays, where Ca 2+ flux response occurs very rapidly after agonist addition (<1 min) while the functional adhesion and chemotaxis assays involve much longer times of incubation with the agonist (10 and 60 min, respectively). Charlton and Vauquelin [48] proposed that the K d value of an antagonist is influenced by its dissociation rate, the agonist's intrinsic efficacy, and the cellular amplification of the signal and that these various influences become more extreme when comparing Ca 2+ assays to functional assays requiring much longer times [48] . In fact, this can result in assay-related antagonist potency inversions, which have been seen for other receptors [48] and may explain the low correlation of EC 50 values observed for some of our compounds in the different assays (e.g., see compound 6). In any case, further kinetic studies on this issue are clearly necessary. Activation by fMLF leads to phosphorylation of ERK1/2 in human neutrophils and FPR1-transfected cells [49] . Thus, we evaluated whether the selected FPR1 antagonists inhibited phosphorylation of ERK1/2 in DMSO-differentiated, neutrophil-like HL60 cells and primary human neutrophils. Pretreatment with the potent FPR1 antagonists 14 and 17 effectively inhibited fMLF-induced phosphorylation of ERK1/2 (Figs. 5A and 6 ). Since differentiated HL60 and neutrophils express both FPR1 and FPR2, we next examined FPR1-transfected RBL (FPR1-RBL) cells. Consistent with our results in differentiated HL60 cells and neutrophils, pretreatment with FPR1 antagonists 14 and 17 inhibited fMLF-induced ERK1/2 phosphorylation in FPR1-HL60 cells with similar potency (Fig. 5B) . Importantly, untransfected RBL cells did not respond to fMLF, and no ERK1/2 phosphorylation was observed (data not shown).
To ensure that the results were not influenced by possible compound toxicity, cytotoxicity of the most potent FPR1 antagonists was evaluated at various concentrations up to 50 mM in wildtype HL60 cells. None of the active FPR1 antagonists affected cell viability at the highest tested concentrations (data not shown), thereby verifying that these compounds were not cytotoxic, at least during the 18-h incubation period.
Molecular modeling of FPR1 antagonists
For molecular modeling, we developed a pharmacophore model of FPR1 antagonists, which was based on the structure of previously reported potent FPR1 antagonists with diverse chemical scaffolds [31] . As designated previously [31] , this pharmacophore template has three hydrophobic sites (Protrusion, Area I, and Area II), one compact grouping of H-bond donors or positively charged centers (Area III), and one region of H-bond acceptors or negatively charged centers (Area IV) (Fig. 7A) . Indeed, overlay of a recently reported FPR1 antagonist, HCH6-1 [(R)-methyl 2-((S)-2-benzamido-3-(1H-indol-3-yl)propanamido)-3-phenylpropanoate] [21, 22] , on the template shows a high level of similarity. Importantly, the Protrusion area is occupied by the indole fragment and a large ''blue" field point is located in Area III (Fig. 7A) , verifying that these two structural features are important for FPR1 antagonist activity and confirming that this pharmacophore template is applicable to FPR1 antagonists of different chemical classes.
A visual inspection of the molecule overlays on the FPR1 template revealed that pyrrole-based FPR1 antagonists occupy three hydrophobic pockets (Area I, Area II, and the Protrusion) with their 
R 4 , phenyl, and aroyl (benzoyl/pyridine) moieties in different combinations (Table 3) . As an example, Fig. 7B shows that the potent FPR1 antagonist 14 superimposes quite well with the template. Thus, we explored optimal alignments of the most potent antagonists and several inactive pyrroles onto the pharmacophore template of FPR1 antagonists using the FieldAlign program. The alignments with higher similarity scores were analyzed in terms of molecular moiety coincidence with key regions in the pharmacophore model described above. The values of similarity scores obtained for the active and inactive pyrroles are presented in Table 3 . According to Field Point methodology [42] , the template reflects the main geometrical and electronic features of a receptor binding site. Hence active and inactive compounds should differ in their level of similarity, and a statistical analysis of similarity scores using ANOVA was performed in order to estimate the difference between the antagonists and inactive compounds in terms of the score values. Notably, a statistically significant difference (P < 0.05) between groups of active and inactive compounds with respect to their similarity scores was found.
The similarity score is an integral quantity. However, structural peculiarities of the alignments can be of greater importance for molecular recognition. Analysis of data in Table 3 shows that most active FPR1 antagonists possess two common features. First, the hydrophobic pocket called the Protrusion is occupied by a moiety of the overlaid molecule. Second, an antagonist molecule in its superimposed conformation produces blue field point(s) in area III where the analogous field points of the template are located. In other words, an antagonist interacts with some positively charged center in the receptor, e.g. forms a H-bond in the FPR1 binding site. These two simple features give correct classifications for 13 active FPR1 antagonists (81% of all the active compounds investigated). Likewise, 12 of the 16 inactive compounds were also classified correctly, as they lacked at least one of these features. However, for the alignments of molecules 28-30, the R 4 group in the Protrusion area extended outside of the template boundaries (see an example for the compound 30 in Fig. 7C) . Thus, an unfavorable orientation of the R 4 substituent results in inactivity of these three compounds despite fulfillment of the other two abovementioned features. Thus, our pharmacophore model [31] can be used to explain differences between 1H-pyrrol-2(5H)-one-based FPR1 antagonists and their inactive analogs.
In order to map the important features of the template onto the FPR1 binding site, we performed a docking study for three pyrrolebased FPR1 antagonists (14, 15, and 17) using MVD software. An homology model of the FPR1 ligand-binding region described previously [45] was taken as a target protein for the docking computations. The FPR1 binding site regions are designated according to our previous publication [45] , where cavity B is restricted by Val160, Leu198, Arg201, Gly202, and Arg205; the bottom D of the binding site is associated with Ala261, Ala264, and Val283; and cavity E is located near Trp91, Trp95, Cys98, and Lys99 (Fig. 8) . Consistent with our pharmacophore modeling above, poses of the three compounds overlaid with each other within the ligand binding site, and the molecular moieties of compounds 14, 15, and 17 overlapped in the same manner as with the pharmacophore template. For example, substituted phenyl rings directly linked to pyrrole heterocycles are mutually overlaid like within the template where they fall into area I. Likewise, the R 4 groups of molecules 14 and 15 and the benzoyl moiety of compound 17 all occupy area II of the template. Similar correspondence between the pharmacophore model and docking results also existed for moieties that fell in the Protrusion region of the template. These observations confirm applicability of the pharmacophore template to predict correct binding modes of pyrrole derivatives to FPR1.
Discussion
FPR1 is a key regulator of the inflammatory environment and may represent unique target for therapeutic drug design. For example, the conventional FPR1 agonist fMLF is involved in the pathogenesis of multiple inflammatory diseases, such as pouchitis, colitis, ulcerative colitis, Crohn's disease and juvenile periodontitis (reviewed in [1] ). Since FPR1 represents a potentially important pharmacological target, significant attention has been focused on the identification of ligands that interact with this receptor and/ or interfere with FPR1-dependent pathways. Although several natural compounds have been reported as FPR1 agonists (reviewed in [28, 30] ), less attention has focused on synthetic FPR1 antagonists. Previously, several 1H-pyrrol-2(5H)-one derivatives were identified as small-molecule competitive FPR1 antagonists [32, 33] . In the current work, we report further characterization and development of related analogs with FPR1 antagonist activity in functional tests using transfected cells and primary neutrophils. Screening of a library of forty-two additional 1H-pyrrol-2(5H)-ones, which are structural derivatives of previously reported competitive FPR1 antagonists 1-3 [32, 33] , resulted in the discovery of novel and potent pyrrole-based FPR1 antagonists. We also showed that these (Table 2) . Neutrophils play an essential role in proper resolution of inflammation, and when these processes are not tightly regulated, neutrophils can trigger positive feedback amplification loops that promote neutrophil chemotaxis, adherence to endothelial cells, and activation, leading to significant tissue damage and evolution toward chronic disease [52] . Recently, Honda et al. [53] demonstrated that FPR1 blockade by cyclosporine H attenuated hepatic ischemia-reperfusion injury by inhibition of neutrophil chemotaxis. Thus, the pyrrole-based FPR1 antagonists reported here and their analogs may offer pharmacological means to treat acute and chronic inflammation by reducing FPR1-dependent neutrophil chemotaxis and adherence to epithelial cells. However, these FPR1 antagonists are active in the micromolar range and further work will be necessary to increase a potency of these inhibitors by scaffold optimization and evaluation of their effectiveness in inflammatory models in vivo. SAR analysis and computer-aided design can be beneficial in the identification of new molecules based on the features of known structures. Comprehensive SAR analysis of all 45 pyrrole analogs suggests that the nature of the group at position R 4 has a major impact on FPR1 antagonist activity. Subsequent molecular modeling also indicated that the presence of a hydrophobic moiety in the Protrusion region of the FPR1-antagonist pharmacophore template [31] and interaction of a ligand with a positively charged group or H-bond donors in the FPR1 binding site were critical for antagonist activity. Our molecular docking results for 1H-pyrrol-2(5H)-ones agreed with the spatial arrangement of the field point pharmacophore template, which was developed based on the structures of previously reported potent FPR1 antagonists with diverse chemical scaffolds [31] . Notably, the docking poses and overlays on the pharmacophore template for chromone-based FPR1 antagonists investigated previously [31] are very similar to the present results. However, some substituted chromones possessed molecules longer in size than the pyrrole derivatives studied here, and substituents in these chromone-based FPR1 antagonists can also occupy channel C of the FPR1 binding site [31] . This detail of the binding mode can be considered less important, taking into account that pyrrole-based FPR1 antagonist occupy mainly bottom D, cavity B, and cavity E (see Fig. 6B ). Importantly, the degree of antagonist pharmacophore template. Arrow indicates a dimethylamino ethyl group of the molecule in the area of the Protrusion, but which extends outside of the template boundaries. In the panels A-C, field points are colored as follows: blue = located near electron-rich groups (produced by a positive probe atom); red = located near electron-deficient groups (produced by a negative probe atom); yellow = van der Waals attractive (steric); and orange = hydrophobic. Molecules of the template are shown with thin backbones and icosahedral field points. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) similarity of the pyrrole FPR1 antagonists to the pharmacophore model is significantly higher as compared to the inactive 1H-pyrrol-2(5H)-ones.
3-Hydroxy-1H-pyrrol-2(5H)-one could serve as a functional building block for the construction of promising molecules with diverse bioactivities. For example, 5-aryl-4-benzoyl-3-hydroxy-1-(2-arylethyl)-2H-pyrrol-2-ones have been identified as competitive and specific vasopressin-2 receptor (V2R) antagonists [54] . Certain 4-aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-one derivatives showed specificity for targeting trypanothione synthetase in Leishmania infantum [55] . Previously, a series of 4-aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones were reported as inhibitors of the annexin A2-S100A10 protein interaction [34] . In the present study, we also evaluated seven relatively potent inhibitors of the annexin A2-S100A10 protein interaction (compounds 7-13) [34] , but these compounds did not exhibit any FPR1 antagonist activity. However, further studies using pyrrole-based FPR1 antagonists compounds will be necessary to evaluate their inhibitory effect on annexin A2-S100A10 protein interaction using published [34] methodology.
In conclusion, we have identified a number of specific, competitive FPR1 antagonists with 1H-pyrrol-2(5H)-one scaffold. Several of these pyrrole derivatives could represent important leads for therapeutic development focused on FPR1 function and attenuation of neutrophil-mediated inflammatory diseases. These compounds can also serve as scaffolds for the development of additional potent and selective FPR1 antagonists. Furthermore, characterization of this class of antagonists and analysis of additional derivatives should provide important clues for understanding the molecular structural requirements of FPR1 antagonists.
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''Yes" and ''No": area was occupied or not, respectively by a molecular fragment. N.A.: No activity was observed at the highest concentration tested in the Ca 2+ flux assay (50 mM) (see Table 2 ).
R-or S-configuration refers to an additional stereocenter in R 4 group of molecule 6.
